Shop All HAT & HT Supplements

HAT Supplement (50X)

Gibco® HAT Supplement is a liquid mixture of sodium hypoxanthine (5 mM), aminopterin (20 µM) and thymidine (0.8 mM). HAT-supplemented medium is suitable for post-fusion selection against unfused or self-fused HGPRT–myeloma cells. Hypoxanthine and thymidine supply preformed purines and pyrimidines for DNA synthesis by hybridomas via the salvage pathway that utilizes HGPRT- contributed by the fused spleen cell. Aminopterin, a folic acid antagonist, inhibits the de novo nucleoside biosynthesis pathway.

Product Use
For Research Use Only. Not for use in diagnostic procedures.

Dual site cGMP Manufacturing and Quality System
For supply chain continuity, we manufacture Gibco® HAT Supplement at two separate facilities located in Grand Island, NY and Scotland, UK. Both sites are compliant with cGMP manufacturing requirements, are certified to ISO 13485, and are registered with the FDA as medical device manufacturers.

HT Supplement (50X)

Gibco® HT Supplement is a liquid mixture of sodium hypoxanthine (5 mM) and thymidine (0.8 mM). HT-supplemented medium is suitable for post-selection rescue to overcome the effects of residual intracellular aminopterin. Once the de novo biosynthesis pathway for nucleosides has been reestablished, HT supplementation can be discontinued.

cGMP Manufacturing and Quality System
Gibco® HT Supplement is manufactured at a cGMP compliant facility, located in Paisley, Scotland, UK. The facility is registered with the FDA as a medical device manufacturer and is certified to the ISO 13485 standard. For supply chain continuity, we offer a comparable Gibco® HT Supplement product made in our Grand Island facility (11067-030). This facility is registered with the FDA as a medical device manufacturer and is certified to the ISO 13485 standards.

HT Supplement (100X) (Gibco™)

Gibco® HT Supplement is a liquid mixture of sodium hypoxanthine (10 mM) and thymidine (1.6 mM). HT-supplemented medium is suitable for post-selection rescue to overcome the effects of residual intracellular aminopterin. Once the de novo biosynthesis pathway for nucleosides has been reestablished, HT supplementation can be discontinued.

cGMP Manufacturing and Quality System
Gibco® HT Supplement is manufactured at a cGMP compliant facility, located in Grand Island, New York. The facility is registered with the FDA as a medical device manufacturer and is certified to ISO 13485 standards. For supply chain continuity, we offer a comparable Gibco® HT Supplement product made in our Scotland facility (41065-012). This facility is registered with the FDA as a medical device manufacturer and is certified to the ISO 13485 standard.